Brilinta package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Brilinta (Ticagrelor)

Apo-Ticagrelor

Ticagrelor

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:

Brilinta

Ticagrelor

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Brilinta (ticagrelor) is a p2y12 platelet inhibitor listed in our Heart and blood pressure medications directory and prescribed for reduction of specified cardiovascular events in eligible patients (1.1) (2.1). Administered via the oral route, Brilinta is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Brilinta is a medication containing the active pharmaceutical ingredient ticagrelor, classified pharmacologically as a p2y12 platelet inhibitor (2.1). It is clinically indicated for the management of reduction of specified cardiovascular events in eligible patients as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Heart and blood pressure medications section of our catalogue, patients and prescribers frequently review Brilinta alongside related therapies such as Apo-Ticagrelor, Acebutolol, Aceon (Perindopril Erbumine), and Acetylsalicylic Acid.

Official Indications and Usage

Brilinta is a P2Y 12 platelet inhibitor indicated (1.1):

  • To reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (acs) or a history of MI. For at least the first 12 months following acs, it is superior to clopidogrel.
  • To reduce the risk of a first MI or stroke in patients with coronary artery disease (cad) at high risk for such events. While use is not limited to this setting, the efficacy of Brilinta was established in a population with type 2 diabetes mellitus (T2DM).
  • To reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (tia).

Mechanism of Action and Pharmacology

Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent. (1.1)

Ordering Brilinta from Canada for U.S. Delivery

U.S. patients can order Brilinta (Ticagrelor) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Brilinta
Chemical / Generic Name Ticagrelor
Pharmacological Class P2Y12 Platelet Inhibitor
Therapeutic Category Heart and blood pressure medications
Molecular Weight 522.57. g/mol (2.1)
Bioavailability ~36% (1.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD)
Routes of Administration Oral
Dosage Forms & Strengths (ticagrelor) 90 mg is supplied as a round, biconvex, yellow, film-coated tablet marked with a “90” above “T” on one side. Brilinta (ticagrelor) 60 mg is
Primary Indications Reduction Of Specified Cardiovascular Events In Eligible Patients
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
FDA UNII Identifier GLH0314RVC
NLM RxNorm Concept ID (RxCUI) 1116635, 1116639, 1666332, 1666334
FDA Application License NDA022433
Official DailyMed SetID f7b3f443-e83d-4bf2-0e96-023448fed9a8
Catalogue Index Links Letter B Index · All Medications · All Categories

Directions

Dosage and Administration Overview

  • Acs or History of MI.
  • Initiate treatment with 180 mg oral loading dose of Brilinta. Then administer 90 mg twice daily during the first year.
  • Patients with cad and No Prior Stroke or MI.
  • Acute Ischemic Stroke.
  • Initiate treatment with a 180 mg loading dose of Brilinta then continue with 90 mg twice daily for up to 30 days. Use Brilinta with a daily maintenance dose of aspirin of 75-100 mg. (1.1)

Presentations and Strengths

(ticagrelor) 90 mg is supplied as a round, biconvex, yellow, film-coated tablet marked with a “90” above “T” on one side. Brilinta (ticagrelor) 60 mg is supplied as a round, biconvex, pink, film-coated tablet marked with “60” above “T” on one side (1.1):

  • 60 mg and 90 mg tablets.

Administration Guidance

Take Brilinta orally at the same time(s) each day as directed on your prescription label (1.1). Check with your pharmacist whether your specific formulation should be taken with a meal or on an empty stomach, and swallow extended-release or film-coated tablets whole without crushing, chewing, or splitting unless the tablet is scored and your prescriber has instructed you to do so.

Missed Dose Guidance

If you miss a scheduled dose of Brilinta, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Brilinta is ticagrelor (2.1).

Excipients and Formulation Carriers

Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).

Cautions and important safety information

Boxed Warning

Warning: bleeding risk (1.1):

  • Brilinta, like other antiplatelet agents, can cause significant, sometimes fatal bleeding.
  • Do not use Brilinta in patients with active pathological bleeding or a history of intracranial hemorrhage.
  • Do not start Brilinta in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1,.
  • 6.1 ).
  • If possible, manage bleeding without discontinuing Brilinta. Stopping Brilinta increases the risk of.
  • Subsequent cardiovascular events..

Contraindications

  • History of intracranial hemorrhage.
  • Active pathological bleeding.
  • Hypersensitivity to ticagrelor or any component of the product. (1.1)

Key Clinical Precautions

Before starting or continuing Brilinta, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Cardiovascular events: Depending on the medication class and underlying medical history, patients should be monitored for signs of cardiovascular events such as chest pain, shortness of breath, sudden weakness, or slurred speech.

Pregnancy, Lactation, and Special Populations

Available data from case reports with Brilinta use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Ticagrelor given to pregnant rats and pregnant rabbits during organogenesis caused structural abnormalities in the offspring at maternal doses about 5 to 7 times the maximum recommended human dose (MRHD) based on body surface area. When ticagrelor was given to rats during late gestation and lactation, pup death and effects on pup growth were seen at approximately 10 times the MRHD. (1.1)

Interactions

Official Drug Interaction Overview

  • Avoid use with strong CYP3A inhibitors or CYP3A inducers.
  • Opioids: Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent.
  • Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.
  • Rosuvastatin plasma concentrations may increase. Monitor for statin-related adverse effects.
  • Monitor digoxin levels with initiation of or any change in Brilinta. (1.1)

Important Interaction Categories

Concomitant use of Brilinta with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Digoxin (such as Lanoxin (Digoxin) or Digoxin Generic): Co-administration can affect P-glycoprotein transport or renal clearance of digoxin, altering serum digoxin concentrations. Appropriate clinical and laboratory monitoring of digoxin levels is advised.
  • Strong CYP3A4 inhibitors and inducers (such as ketoconazole, itraconazole, clarithromycin, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort): Co-administration with strong CYP3A4 inhibitors can significantly increase plasma concentrations and side-effect risk, whereas CYP3A4 inducers can decrease systemic exposure and reduce efficacy.
  • Opioid analgesics and central nervous system depressants: Concomitant use can result in additive central nervous system depression, profound sedation, or slowed respiratory rate.

Side effects

Like all medications, Brilinta can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; taking oral doses with food (when permitted by the label) may help.
  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Dizziness or lightheadedness: May occur especially when standing up quickly from a sitting or lying position (orthostatic changes); rise slowly and stay well hydrated.
  • Skin rash: Mild skin eruptions can occur; seek immediate care if a rash blisters, peels, or is accompanied by fever.

Clinical Trial and Postmarketing Adverse Reactions

The following adverse reactions are also discussed elsewhere in the labeling (1.1):

  • Bleeding.

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

(ticagrelor) 90 mg is supplied as a round, biconvex, yellow, film-coated tablet with a “90” above “T” on one side: Bottles of 60 -. (1.1)

Store Brilinta in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).

Frequently Asked Questions About Brilinta

What is Brilinta and what active ingredient does it contain?

Brilinta is a p2y12 platelet inhibitor containing the active pharmaceutical ingredient ticagrelor. It is supplied for oral administration and requires a valid prescription where applicable.

How does Brilinta work in the body?

Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.

What conditions is Brilinta prescribed to treat?

Brilinta is primarily indicated for reduction of specified cardiovascular events in eligible patients. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Brilinta?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Brilinta is administered via the oral route. Take it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Brilinta?

Commonly reported side effects of Brilinta include feeling sick, loose stools, dizziness, and rash. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Brilinta?

Important interaction categories for Brilinta include digoxin, medicines that strongly affect CYP3A enzymes, and opioids. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Brilinta be used during pregnancy or breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Brilinta to weigh the clinical benefits and potential risks.

Do I need a prescription to buy Brilinta online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Brilinta (Ticagrelor) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Brilinta have a generic equivalent (Ticagrelor) at a Canada pharmacy?

Currently, Brilinta (Ticagrelor) is dispensed in our catalogue as a brand-name formulation. Check our Ticagrelor active ingredient hub for updates as licensed generic presentations become available.

How is Brilinta shipped to U.S. residents, and how much does shipping cost?

Brilinta ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Brilinta prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Brilinta prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Brilinta (Ticagrelor) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Brilinta (Ticagrelor), Official Prescribing Information. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).

Related Guides

Call 1-888-868-1920Help